Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – What’s Next?

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s share price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $13.90 and traded as low as $8.21. Seres Therapeutics shares last traded at $8.65, with a volume of 58,265 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $14.33.

Seres Therapeutics Stock Up 6.0%

The company has a market capitalization of $78.28 million, a PE ratio of -2.42 and a beta of 0.22. The firm has a 50-day moving average of $13.90 and a two-hundred day moving average of $16.52.

Institutional Trading of Seres Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 3,918 shares in the last quarter. 683 Capital Management LLC purchased a new position in shares of Seres Therapeutics in the 4th quarter valued at about $778,000. ExodusPoint Capital Management LP acquired a new position in Seres Therapeutics in the 4th quarter worth about $190,000. OMERS ADMINISTRATION Corp purchased a new position in Seres Therapeutics during the fourth quarter worth approximately $214,000. Finally, Barclays PLC grew its holdings in Seres Therapeutics by 427.8% in the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 6,024 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.